ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1325

Age Effects Joint Space Narrowing in Early Active Rheumatoid Arthritis Patients

Xanthe M.E. Matthijssen1, Gülsah Akdemir1, Iris M. Markusse2, Yvonne P. Goekoop-Ruiterman3, K. Huub Han4, Annekoos L. Huidekoper5, Pit J.S.M. Kerstens6, Willem F. Lems7, T. W. J. Huizinga1 and Cornelia F. Allaart1, 1Rheumatology, LUMC, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3Rheumatology, HAGA hospital, The Hague, Netherlands, 4Rheumatology, Maasstad hospital, Rotterdam, Netherlands, 5Rheumatology, Bronovo hospital, The Hague, Netherlands, 6Department of Rheumatology, Reade, Amsterdam, Netherlands, 7Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Early Rheumatoid Arthritis, Elderly, joint damage, osteoarthritis and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Joint space narrowing (JSN)
and erosions are the major radiologic markers of radiographic progression in
rheumatoid arthritis (RA), as scored by the Sharp/van der Heijde score (SHS).
JSN may also be a manifestation of (primary) osteoarthritis becoming more
prominent with age. We hypothesize that the severity of JSN progression and predictors
of JSN progression may differ between older and younger RA patients.

Methods:

Ten year follow-up data of
the BeSt study, a randomized controlled treat-to-target (Disease activity score
(DAS)≤2.4) trial in early RA were used. Annual X-rays of hands and feet
from baseline to year 10 were scored with the SHS by two independent readers,
blinded for patient identity and time order. Subgroups were defined by age at
baseline: ≥55 (median age), ≥40<55 and <40 years. Poisson
regression with multiple imputation for missing data (7% and 45% of the
radiographs at baseline and year 10) was used to identify univariate
predictors. Factors with p<0.2 were entered in a multivariate regression
analysis. Post-hoc Bonferroni corrections were used to correct for multiple
testing.

Results:

Baseline median
(interquartile) SHS scores were higher in patients ≥55 compared to the
other groups (≥55: 2.5 (1.0-7.4); ≥40<55: 1.0 (0.0-4.5); <40:
1.0 (0.0-3.0); p≤0.001). Also, higher baseline JSN was observed in
patients ≥55 compared to the other groups: 2.0 (0.0-6.0), 1.0 (0.0-3.0)
and 0.3 (0.0-3.0), p≤0.001, respectively. After ten years, total JSN and
SHS scores were similar in all age-groups. Although fewer patients <40 years
appear to have JSN progression, if they do show JSN progression it is more
severe (figure 1).

Table 1 shows significant
univariate risk factors. In the multivariate regression, in patients ≥55
mean erythrocyte sedimentation rate (ESR) over ten years follow-up (RR 1.02,
95% CI (1.00-1.03)) and the combined presence of rheumatoid factor and
anti-citrullinated protein antibodies (RF+/ACPA+) (3.27 (1.25-8.53)) were
significantly associated with JSN progression. In patients ≥40<55 no significant
risk factors were revealed. In patients <40 baseline swollen joint count
(SJC) (1.09 (1.01-1.18)) and mean ESR (1.04 (1.02-1.06)) were significantly associated.

Conclusion:

At baseline, RA patients
≥55 years had more JSN but after 10 years of DAS≤2.4 targeted
treatment they do not show more often or more severe JSN progression. Independent
risk factors for JSN progression were mean ESR in patients <40 and those ≥55
years, RF+/ACPA+ in patients ≥55 years and SJC in patients <40 years.
This suggests that mechanisms leading to JSN progression vary between age
groups.

 


Disclosure: X. M. E. Matthijssen, None; G. Akdemir, None; I. M. Markusse, None; Y. P. Goekoop-Ruiterman, None; K. H. Han, None; A. L. Huidekoper, None; P. J. S. M. Kerstens, None; W. F. Lems, None; T. W. J. Huizinga, Merck, UCB, Bristol Myers Squibb, Biotest AG, Pfizer, GSK, Novartis, Roche, Sanofi-Aventis, Abbott, Crescendo Bioscience, Nycomed, Boeringher, Takeda, Zydus, Epirus and Eli Lilly, 5; C. F. Allaart, None.

To cite this abstract in AMA style:

Matthijssen XME, Akdemir G, Markusse IM, Goekoop-Ruiterman YP, Han KH, Huidekoper AL, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF. Age Effects Joint Space Narrowing in Early Active Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/age-effects-joint-space-narrowing-in-early-active-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/age-effects-joint-space-narrowing-in-early-active-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology